AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02129218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dietary Intervention
Description: Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
Study NCT02129218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified Dietary Intervention
Description: Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
Study NCT05143801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise with surgical face mask in a temperate environment
Description: Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
Study NCT05143801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise with surgical face mask in a hot environment
Description: Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
Study NCT02129218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensified Dietary Intervention
Description: Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
Study NCT02129218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic load
Study NCT02129218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium Glycemic Load
Study NCT00735332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-232
Description: 21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
Study NCT03811600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PD1/PD-L1 exosomal expression
Description: exosomal PD1/PD-L1 expression
Study NCT01525212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, ≤ 25 mg, Once daily, 3 days
Study NCT01525212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, ≤ 100 mg, Once daily, 3 days
Study NCT01525212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, ≤ 400 mg, Once daily, 3 days
Study NCT02520128 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
Study NCT01525212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
Study NCT01525212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-929075
Description: Oral Suspension, 0 mg, Once daily, 3 days
Study NCT01525212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-929075
Description: Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
Study NCT03320733 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual energy CT scan with subtraction imaging
Description: The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT.
Study NCT02436798 — intervention group
Intervention type: DRUG
Intervention: Ondansetron
Description: All patients will be receiving treatment with ondansetron as part of standard care.
Study NCT03558412 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CODOX-M/IVAC
Description: Given ivgtt
Study NCT03558412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given ivgtt
Study NCT04307745 — intervention group
Intervention type: OTHER
Intervention: Primary prevention
Description: The primary prevention that the 4 groups put in place for the upper limp athletes
Study NCT00035815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin like growth factor, type 1
Description: 0.05 mg per kg body weight given subcutaneously twice daily
Study NCT00035815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
Study NCT02796989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bran
Description: 20 g each day
Study NCT04432298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Sterile liquid for injection
Study NCT04432298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile liquid for injection
Study NCT02796989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 g each day
Study NCT04795180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigations trough the efferent limb of loop ileostomy
Description: Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
Study NCT03915054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AREG-TRIGGER
Description: Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media.
Study NCT03915054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL-TRIGGER
Description: Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
Study NCT01881633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302
Study NCT04795180 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Irrigations trough the efferent limb of loop ileostomy
Description: Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
Study NCT05143801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval exercise without using a surgical face mask in a hot environment
Description: Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
Study NCT05143801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval exercise without using a surgical face mask in a temperate environment
Description: Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
Study NCT00973219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
Description: Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
Study NCT01726933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41008
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
Study NCT01726933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LASW1835
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
Study NCT01726933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
Study NCT01002287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SprayShield Adhesion Barrier System
Description: Adhesion Barrier Device
Study NCT01002287 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Good Surgical Technique Alone
Description: Good Surgical Technique Alone
Study NCT02742389 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preprocedure Telephone Call
Description: The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
Study NCT04430530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20
Description: Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
Study NCT01881633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01336972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan was supplied as 15 and 30 mg tablets.
Study NCT03749174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long acting Supraclivicular block vs Short acting Supraclavicular block
Description: Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block
Study NCT00176254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 80 centigray (cGy) on Day 1 \& 2 and 22 \& 23 of chemotherapy
Study NCT00176254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 225 mg/m2 intravenously over three hours on Days 1 and 22
Study NCT00176254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
Study NCT00440739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: etoricoxib 120 mg
Study NCT00440739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flavoxate
Description: flavoxate 200 mg 3 times
Study NCT02095730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epithelium-On Riboflavin
Description: Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
Study NCT00440739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib, flavoxate
Description: etoricoxib 120 mg once and flavoxate 200 mg 3 times
Study NCT00440739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once and placebo 3 times
Study NCT04952688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OCT- Angiographie
Description: Ophthalmological examinations
Study NCT02618733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg, twice a day
Study NCT02618733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg, once a day
Study NCT02327247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine
Description: Extended Release Tablets, 10mg
Study NCT02327247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLENDIL®
Description: Extended Release Tablets, 10mg
Study NCT00781664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Cream SF Vehicle, Daily for up to 21 days
Study NCT00781664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Cream SF, 0.3%, Daily for up to 21 days
Study NCT02147379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Study NCT02606032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: active comparator
Study NCT02606032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: active comparator
Study NCT02606032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: active comparator
Study NCT00781664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Cream SF, 1%, Daily for up to 21 days
Study NCT00781664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel Vehicle, Daily for up to 21 days
Study NCT02095730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epithelium-Off Riboflavin
Description: Riboflavin 0.1% Phosphate Sodium solution
Study NCT02095730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV Light - Continuous Beam
Description: 5 minutes of constant UV exposure to saturated cornea
Study NCT02095730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV Pulsed Beam
Description: 5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
Study NCT01646294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 modified release (OCAS)
Description: oral
Study NCT01646294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 immediate release (IR)
Description: oral
Study NCT00781664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 1.5%, Daily for up to 21 days
Study NCT00781664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 2.5%, Daily for up to 21 days
Study NCT01687621 — intervention group
Intervention type: PROCEDURE
Intervention: Diagnostic Algorithm for Community Based Worker for Omphalitis
Description: After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
Study NCT02606032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebos to all antibiotics
Study NCT00781664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 5%, Daily for up to 21 days
Study NCT00781664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 7.5%, Daily for up to 21 days
Study NCT01351519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
Study NCT01910662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KLH 0.1 mg
Description: KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
Study NCT01910662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KLH 5 mg
Description: KLH will be administered as single SC injection of 5 mg
Study NCT01910662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBS (0.1 mL)
Description: PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
Study NCT03419247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh tumor tissue biopsy
Description: A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
Study NCT00781664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Lauryl Sulfate
Description: Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Study NCT02551809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-311
Description: Intramuscular injection
Study NCT02551809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection
Study NCT02551809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT02740582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone
Study NCT01910662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculin PPD
Description: Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
Study NCT02740582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Study NCT02740582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02740582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02424786 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STOPP/START criteria
Description: Evaluation of medication lists
Study NCT02731768 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
Study NCT02731768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support-enhanced
Description: Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
Study NCT01606722 — intervention group
Intervention type: DRUG
Intervention: Darunavir/ritonavir
Description: Darunavir/ritonavir (800/100 mg once daily) monotherapy
Study NCT02731768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Zip
Study NCT02731768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Zip
Study NCT02731768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital body weight scale
Study NCT02731768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital body weight scale
Study NCT01460836 — intervention group
Intervention type: DRUG
Intervention: Tobramycin solution for inhalation
Study NCT01460836 — intervention group
Intervention type: DRUG
Intervention: Aztreonam lysine for inhalation
Study NCT02628223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Description: The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.